{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:52:19Z","timestamp":1762105939997,"version":"build-2065373602"},"reference-count":61,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Alzheimer's disease and related diseases (ADRD) is a progressive and inexorable disease. In France, acetylcholinesterase inhibitors and memantine were reimbursed for subjects with ADRD, until 2 modifications of their reimbursement rate (2012, 2018). We aimed to study the consequences of these measures on ADRD subjects' healthcare use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analysed data from the FRA\u2010DEM cohort, including subjects with presumed incident ADRD identified since 2011 in the French health insurance system. We studied the healthcare use of subjects identified with incident ADRD in 2011, 2013, 2015, 2017 and 2019, notably the annual number of defined daily doses of various psychotropic groups. We performed 2 multivariate multinomial logistic regressions with the subcohort year as the dependent variable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 165\u2009120 subjects were included. A progressive decrease in exposure to antidementia drugs was observed between 2011 and 2019. Consultations with private neurologists or psychiatrists, and exposure to risperidone, antidepressants and benzodiazepines increased in the 2019 subcohort, following the 2018 reimbursement withdrawal. Meanwhile, the use of nursing\/allied healthcare and emergency care increased over the subcohort years, whereas we observed a decrease in general practitioner consultations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results suggest increases in private neurologist or psychiatrist consultations and exposure to recommended drugs after the reimbursement withdrawal, contrary to the fears expressed. However, antidementia drug exposure decreased long before the reimbursement modifications, probably due to the growing evidence of the modest effect of these drugs, and exposure to benzodiazepines increased after the reimbursement withdrawal.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.16143","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T23:20:26Z","timestamp":1719444026000},"page":"2582-2596","source":"Crossref","is-referenced-by-count":2,"title":["Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA\u2010DEM cohort"],"prefix":"10.1111","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-374X","authenticated-orcid":false,"given":"Ana\u00efs","family":"Couret","sequence":"first","affiliation":[{"name":"Agence R\u00e9gionale de Sant\u00e9 Occitanie  Toulouse France"},{"name":"Maintain Aging Research team, CERPOP, Universit\u00e9 de Toulouse, Inserm Universit\u00e9 Paul Sabatier  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Gardette","sequence":"additional","affiliation":[{"name":"Maintain Aging Research team, CERPOP, Universit\u00e9 de Toulouse, Inserm Universit\u00e9 Paul Sabatier  Toulouse France"},{"name":"Centre Hospitalier Universitaire de Toulouse, Department of Epidemiology and Public Health  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Renoux","sequence":"additional","affiliation":[{"name":"Centre d'Investigation Clinique 1436, Team M\u00e9DatAS \"M\u00e9thodologie, Data management et Analyses Statistiques\", Centre Hospitalier Universitaire de Toulouse, Inserm Universit\u00e9 Paul Sabatier  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[{"name":"Centre d'Investigation Clinique 1436, Team PEPSS \"Pharmacologie En Population cohorteS et biobanqueS\", Centre Hospitalier Universitaire de Toulouse, Inserm Universit\u00e9 Paul Sabatier  Toulouse France"},{"name":"Centre Hospitalier Universitaire de Toulouse, Department of Pharmacology  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"volume-title":"Global status report on the public health response to dementia","year":"2021","author":"World Health Organization","key":"e_1_2_11_2_1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)32205\u20104"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(16)00062\u20104"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)31363\u20106"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190.pub2"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747.pub3"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub5"},{"key":"e_1_2_11_11_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Transparency committee opinion on memantine\u2019 2007. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2010-03\/ebixa_ct_3046.pdf"},{"key":"e_1_2_11_12_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Avis de la commission de la transparence sur le donepezil\u2019 2007. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/ct-3132_aricept.pdf"},{"key":"e_1_2_11_13_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Avis de la commission de la transparence sur la galantamine\u2019 2007. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/ct-3146_reminyl_2007_09_27__14_56_33_421.pdf"},{"key":"e_1_2_11_14_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Avis de la commission de la transparence sur la rivastigmine\u2019 2007. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2010-09\/exelon_-_ct-5099.pdf"},{"key":"e_1_2_11_15_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Transparency committee opinion on memantine\u2019 2011. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2013-01\/ebixa_ct_10677.pdf"},{"key":"e_1_2_11_16_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Transparency committee opinion on donepezil\u2019 2011. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2013-01\/aricept_ct_10755.pdf"},{"key":"e_1_2_11_17_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Transparency committee opinion on galantamine\u2019 2011. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/ct-3146_reminyl_2007_09_27__14_56_33_421.pdf"},{"key":"e_1_2_11_18_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Transparency committee opinion on rivastigmine\u2019 2011. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2010-09\/exelon_-_ct-5099.pdf"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191.pub3"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123289"},{"key":"e_1_2_11_21_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Brief summary of the transparency committee opinion on memantine and cholinesterase inhibitors\u2019 2016. Accessed: May 26 2023. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2017-05\/dir24\/aricept_exelon_reminyl_ebixa_summary.pdf"},{"key":"e_1_2_11_22_1","unstructured":"deLinaresP. \u2018D\u00e9remboursement des m\u00e9dicaments Anti\u2010Alzheimer: On a oubli\u00e9 les malades \u00e0 corps de Lewy et les parkinsoniens\u2019 2018 [Online]. Available:https:\/\/www.franceparkinson.fr\/wp-content\/uploads\/2018\/07\/D%C3%A9remboursement-corps-de-Lewy.pdf"},{"key":"e_1_2_11_23_1","unstructured":"France Alzheimer et Maladies Apparent\u00e9es. \u2018D\u00e9remboursement des m\u00e9dicaments anti\u2010Alzheimer et apr\u00e8s?\u2019 France Alzheimer 2018. Accessed: Jul. 21 2023. [Online]. Available: ."},{"key":"e_1_2_11_24_1","unstructured":"France Alzheimer et Maladies Apparent\u00e9es. \u2018D\u00e9remboursement des m\u00e9dicaments dits <<anti\u2010Alzheimer>>: le Conseil d'Etat saisi!\u2019 France Alzheimer 2018. Accessed: Jul 21 2023. [Online]. Available:"},{"key":"e_1_2_11_25_1","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de G\u00e9riatrie et G\u00e9rontologie \u2018Communiqu\u00e9 de presse officiel: \u201cLe d\u00e9remboursement des m\u00e9dicaments contre la Maladie d'Azheimer\u201d\u2019 Soci\u00e9t\u00e9 Fran\u00e7aise de G\u00e9riatrie et G\u00e9rontologie (SFGG). Accessed: Jul. 21 2023. [Online]. Available:https:\/\/sfgg.org\/actualites\/communique-de-presse-officiel-le-deremboursement-des-medicaments-contre-la-maladie-dazheimer-juin-2018\/"},{"key":"e_1_2_11_26_1","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de G\u00e9riatrie et G\u00e9rontologie \u2018D\u00e9remboursement des m\u00e9dicaments anti\u2010Alzheimer: la SFGG et plusieurs autres organisations saisissent le Conseil d'\u00c9tat\u2019 Soci\u00e9t\u00e9 Fran\u00e7aise de G\u00e9riatrie et G\u00e9rontologie (SFGG). Accessed: Jul 21 2023. [Online]. Available:https:\/\/sfgg.org\/actualites\/deremboursement-des-medicaments-anti-alzheimer-la-sfgg-dautres-societes-savantes-et-associations-ont-saisi-le-conseil-detat\/"},{"key":"e_1_2_11_27_1","unstructured":"Alzheimer Europe \u2018European Dementia Monitor 2023\u2014Comparing and benchmarking national dementia strategies and policies\u2019 2023. Accessed: Apr. 05 2024. [Online]. Available:https:\/\/www.alzheimer-europe.org\/sites\/default\/files\/2023-12\/307767_ALZHEIMER%20EUROPE%20_European%20Dementia%20Monitor_2023_V7.pdf"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2023.01.009"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010017\u20102620\u20106"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2017.12.006"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2021.01.085"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14256"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac053"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000312"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2020.02.019"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5849"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102458\u20109\u201033"},{"key":"e_1_2_11_39_1","unstructured":"Caisse Nationale d'Assurance Maladie (CNAM) \u2018M\u00e9thodologie m\u00e9dicale de la cartographie des pathologies et des d\u00e9penses version G7 (ann\u00e9es 2012 \u00e0 2018)\u2019 2020. Accessed: Aug. 28 2023. [Online]. Available:https:\/\/assurance-maladie.ameli.fr\/sites\/default\/files\/2020_methode-reperage-pathologies_cartographie.pdf"},{"key":"e_1_2_11_40_1","unstructured":"World Health Organization \u2018ATC\/DDD Index\u2019. Accessed: Feb 16 2023. [Online]. Available:https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877\u2010017\u20100621\u20102"},{"key":"e_1_2_11_42_1","unstructured":"Agency for Healthcare Research and Quality \u2018Quality Indicators\u2019. Accessed: May 26 2021. [Online]. Available:https:\/\/www.qualityindicators.ahrq.gov\/Modules\/PQI_TechSpec_ICD10_v2020.aspx"},{"key":"e_1_2_11_43_1","unstructured":"Stats ATIH. \u2018Indicateurs de coordination|Stats ATIH\u2019. Accessed: May 26 2021. [Online]. Available:https:\/\/www.scansante.fr\/applications\/indicateurs-de-coordination"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16178"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2253"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17151"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009444.pub3"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190.pub3"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub6"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009081.pub2"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4583"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883\u2010023\u201003191\u2010w"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15767"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.10.006"},{"key":"e_1_2_11_55_1","unstructured":"Alzheimer Europe. \u2018National Dementia Strategies in France\u20192019. Accessed: Sep. 07 2023. [Online]. Available:https:\/\/www.alzheimer-europe.org\/policy\/national-dementia-strategies\/france"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2556"},{"key":"e_1_2_11_57_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Guide parcours de soins des patients pr\u00e9sentant un trouble neurocognitif associ\u00e9 \u00e0 la maladie d'Alzheimer ou \u00e0 une maladie apparent\u00e9e\u2019 2018. Accessed: Aug. 28 2023. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2018-05\/parcours_de_soins_alzheimer.pdf"},{"key":"e_1_2_11_58_1","article-title":"Data professionnels de sant\u00e9 lib\u00e9raux\u2014Data ameli","author":"Assurance Maladie","year":"2023","journal-title":"Accessed"},{"key":"e_1_2_11_59_1","unstructured":"Haute Autorit\u00e9 de Sante \u2018Comment am\u00e9liorer la qualit\u00e9 et la s\u00e9curit\u00e9 des prescriptions de m\u00e9dicaments chez la personne \u00e2g\u00e9e ?\u2019 2014. [Online]. Available:https:\/\/has-sante.fr\/upload\/docs\/application\/pdf\/2014-10\/fpcs_prescription_web.pdf"},{"key":"e_1_2_11_60_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 \u2018Cadre r\u00e9f\u00e9rentiel ETP Paerpa Polypathologie\u2014Polym\u00e9dication\u2019 2014. [Online]. Available:https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2014-09\/cadre_referentiel_etp_paerpa__polypathologie.pdf"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4804"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010020\u201000817\u20103"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:03:52Z","timestamp":1750305832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/bcp.16143"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16143","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}